Forte Biosciences
FBRX
74 hedge funds and large institutions have $56.4M invested in Forte Biosciences in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 19 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
4% more call options, than puts
Call options by funds: $1.68M | Put options by funds: $1.62M
0% less ownership
Funds ownership: 0.1% → 0.09% (-0%)
5% less funds holding
Funds holding: 78 → 74 (-4)
11% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 19
37% less capital invested
Capital invested by funds: $89.7M → $56.4M (-$33.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$5.3M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.56M |
| 3 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$913K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$827K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$765K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
-$2.64M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$2.05M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.01M |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$905K |
FBRX Hedge Fund Activity: Q2 2019 in Review
74 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q2 2019, worth a combined $56.4M — down 37% from $89.7M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of FBRX and 17 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 22 added.
The largest buyer was Sectoral Asset Management, opening a new position worth an estimated $5.3M. The largest seller was Axa, exiting entirely with an estimated $2.64M sold.
- 74 institutional investors held Forte Biosciences (FBRX) as of Q2 2019, down from 78 in Q1 2019.
- Funds reported $56.4M of Forte Biosciences stock for Q2 2019, down 37% quarter-over-quarter.
- 17 funds opened new Forte Biosciences positions in Q2 2019 and 19 closed out, a net change of -2 holders.
- The largest Forte Biosciences buyer in Q2 2019 was Sectoral Asset Management, an estimated $5.3M added.
- The largest Forte Biosciences seller in Q2 2019 was Axa, an estimated $2.64M sold.
Based on aggregated 13F filings for Q2 2019.